IL6 and neoplasm: In clinical settings, assessing dynamic changes in serum IL-6/IL-8 levels combined with tumor markers through periodic measurements, typically 2–3 times after initiating therapy, could quickly and reliably forecast the effectiveness of treatment with anti-PD-1/PD-L1, especially when imaging evaluations yield inconclusive results.